Citi raised the firm’s price target on Ascendis Pharma to $182 from $146 and keeps a Buy rating on the shares. The company reported 2023 results and provided an update on its key pipeline programs, the analyst tells investors in a research note. The firm says managemewbt expects Skytrofa’s ramp to continue despite competition. Citi sees strong momentum in Ascendis’ commercial business and a favorable risk/reward into 2024 catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
- Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Is ASND a Buy, Before Earnings?
- Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
- Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
